Alnylam: the TTR franchise test
Alnylam guides TTR net product revenue to $4.2B–$4.5B for AMVUTTRA and ONPATTRO. The franchise question excludes GIVLAARI, OXLUMO and collaboration income.
Alnylam Pharmaceuticals / ALNYPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
Alnylam Q3 2026 results and guidancePublished 2026-10-29
Potential outcome market
Will Alnylam 2026 TTR net product revenue exceed $4.35 billion?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.